Literature DB >> 11313683

Recombinant human granulocyte colony-stimulating factor (rh-G-CSF) may accelerate hematopoietic recovery after HLA-identical sibling allogeneic peripheral blood stem cell transplantation.

M Ozcan1, C Ustün, E Akçağlayan, H Akan, O Arslan , O Ilhan, M Beksaç, G Gürman, T Demirer, M Arat, H Celebi, N Konuk, A Uysal, H Koç.   

Abstract

We studied the effects of recombinant human granulocyte colony-stimulating factor (G-CSF) on hematopoietic recovery and clinical outcome in patients undergoing allogeneic peripheral blood stem cell (PBSC) transplantation. Fifty-six patients with hematological malignancies who underwent allogeneic PBSC transplantation between 1995 and 1998 were entered into this study. Twenty-eight patients who received daily G-CSF from day +1 after allogeneic PBSC transplantation until the absolute neutrophil count (ANC) reached >0.5 x 10(9)/l for 3 consecutive days were compared with 28 patients (control group) who did not receive G-CSF in a non-randomized manner. The study group and the control group were comparable with respect to baseline patient and transplantation characteristics. Median times to ANC of >0.5 x 10(9)/l and 1 x 10(9)/l with or without G-CSF were 12 days (range 8-21), 13 days (10-32) (P = 0.04) and 13 days (9-21), 15 days (11-44) (P = 0.02), respectively. Median times to reach a platelet count of >20 x 10(9)/l with and without G-CSF were 11 days (0-20) and 13 days (9-26), respectively (P = 0.03). The incidence of febrile episodes was significantly lower with G-CSF, 75% vs 100% (P = 0.008). Patients receiving G-CSF had less grade III-IV mucositis than those who did not receive G-CSF (P = 0.01). There was also no increase in the incidence and severity of acute GVHD in patients using G-CSF (P = 0.22). Although the number of relapsing patients was greater in the G-CSF group (seven vs three patients), this was not statistically significant (P = 0.24). Disease-free and overall survival rates did not differ between the two groups (P = 0.58 and 0.53, respectively). The administration of G-CSF after allogeneic PBSC transplantation provided faster neutrophil and platelet engraftment associated with less severe mucositis and less febrile episodes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11313683     DOI: 10.1038/sj.bmt.1702816

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  6 in total

1.  Leukocyte cell population analysis from the coulter automatic blood cell analyzer DxH800 to monitor the effect of G-CSF.

Authors:  Sung-Eun Lee; Jihyang Lim; Yonggoo Kim; Woo-Sung Min; Kyungja Han
Journal:  J Clin Lab Anal       Date:  2012-05       Impact factor: 2.352

2.  A Phase 3, Randomized, Placebo-controlled Trial of Filgrastim in Patients with Haematological Malignancies Undergoing Matched-related Allogeneic Bone Marrow Transplantation.

Authors:  Peter Ernst; Andrea Bacigalupo; Olle Ringdén; Tapani Ruutu; Hans J Kolb; Susan Lawrinson; Tomas Skacel
Journal:  Arch Drug Inf       Date:  2008-12

3.  High incidence of severe acute graft-versus-host disease with tacrolimus and mycophenolate mofetil in a large cohort of related and unrelated allogeneic transplantation patients.

Authors:  Zaid Al-Kadhimi; Zartash Gul; Wei Chen; Daryn Smith; Muneer Abidi; Abhinav Deol; Lois Ayash; Lawrence Lum; Edmund K Waller; Voravit Ratanatharathorn; Joseph Uberti
Journal:  Biol Blood Marrow Transplant       Date:  2014-04-04       Impact factor: 5.742

4.  Bacterial blood stream infections (BSIs), particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantation.

Authors:  Celalettin Ustun; Jo-Anne H Young; Genovefa A Papanicolaou; Soyoung Kim; Kwang Woo Ahn; Min Chen; Hisham Abdel-Azim; Mahmoud Aljurf; Amer Beitinjaneh; Valerie Brown; Jan Cerny; Saurabh Chhabra; Mohamed A Kharfan-Dabaja; Parastoo B Dahi; Andrew Daly; Christopher E Dandoy; Christopher C Dvorak; Cesar O Freytes; Shahrukh Hashmi; Hillard Lazarus; Per Ljungman; Taiga Nishihori; Kristin Page; Sai R K Pingali; Ayman Saad; Bipin N Savani; Daniel Weisdorf; Kirsten Williams; Baldeep Wirk; Jeffery J Auletta; Caroline A Lindemans; Krishna Komanduri; Marcie Riches
Journal:  Bone Marrow Transplant       Date:  2018-12-13       Impact factor: 5.483

5.  The effect of granulocyte colony-stimulating factor dose and administration interval after allogeneic hematopoietic cell transplantation on early engraftment of neutrophil and platelet.

Authors:  Leila Noorazar; Hossein Bonakchi; Ghazaleh Sankanian; Sayeh Parkhideh; Maryam Salimi; Abbas Hajifathali; Reza Mirfakhraie; Elham Roshandel
Journal:  J Clin Lab Anal       Date:  2021-10-21       Impact factor: 2.352

6.  Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study.

Authors:  Hui Liu; Xiao Zhai; Zhaoyang Song; Jing Sun; Yang Xiao; Danian Nie; Yu Zhang; Fen Huang; Hongsheng Zhou; Zhiping Fan; Sanfang Tu; Yonghua Li; Xutao Guo; Guopan Yu; Qifa Liu
Journal:  J Hematol Oncol       Date:  2013-02-08       Impact factor: 17.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.